Giergiczny M, Dekker T, Hess S, Chintakayala P. Testing the stability of utility parameters in repeated best, repeated best-worst and one-off best-worst studies. Eur J Trans Infra. 2017 Sep 1;17(4):457-76. doi: 10.18757/ejtir.2017.17.4.3209
Rubinat E, Marsal JR, Vidal T, Cebrian C, Falguera M, Vilanova MB, Betriu A, Fernandez E, Franch J, Mauricio D. Subclinical carotid atherosclerosis in asymptomatic subjects with type 2 diabetes mellitus. J Cardiovasc Nurs. 2016 Mar;31(2):E1-7. doi: 10.1097/JCN.0000000000000236
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.